Effectiveness analysis and value incommensurability
(2025) In Cost Effectiveness and Resource Allocation 25.- Abstract
- This paper argues that in many contexts where effectiveness analysis such as benefit-cost analysis and cost-
effectiveness analysis is used, we have good reason to think that some benefits or costs are incommensurable in
value such that neither can be determined to be better than the other, although they cannot be determined to be
equally good either. Two responses to such value incommensurability are outlined: abandoning conventional ways
of measuring benefits and costs and replacing one-dimensional measures with multi-dimensional measures or
sticking to conventional ways of measuring benefits and costs and accepting that whatever valuation one comes
up with, it will fail to reflect the actual values and value... (More) - This paper argues that in many contexts where effectiveness analysis such as benefit-cost analysis and cost-
effectiveness analysis is used, we have good reason to think that some benefits or costs are incommensurable in
value such that neither can be determined to be better than the other, although they cannot be determined to be
equally good either. Two responses to such value incommensurability are outlined: abandoning conventional ways
of measuring benefits and costs and replacing one-dimensional measures with multi-dimensional measures or
sticking to conventional ways of measuring benefits and costs and accepting that whatever valuation one comes
up with, it will fail to reflect the actual values and value relations between benefits and costs. Both responses are
argued to be problematic. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/ba817dbe-d7cb-4879-8af7-a29d7ca27861
- author
- Herlitz, Anders LU
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cost Effectiveness and Resource Allocation
- volume
- 25
- pages
- 8 pages
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:40269918
- scopus:105003283124
- ISSN
- 1478-7547
- DOI
- 10.1186/s12962-025-00624-w
- language
- English
- LU publication?
- yes
- id
- ba817dbe-d7cb-4879-8af7-a29d7ca27861
- date added to LUP
- 2025-04-24 15:45:26
- date last changed
- 2025-06-01 04:04:37
@article{ba817dbe-d7cb-4879-8af7-a29d7ca27861, abstract = {{This paper argues that in many contexts where effectiveness analysis such as benefit-cost analysis and cost-<br/>effectiveness analysis is used, we have good reason to think that some benefits or costs are incommensurable in<br/>value such that neither can be determined to be better than the other, although they cannot be determined to be<br/>equally good either. Two responses to such value incommensurability are outlined: abandoning conventional ways<br/>of measuring benefits and costs and replacing one-dimensional measures with multi-dimensional measures or<br/>sticking to conventional ways of measuring benefits and costs and accepting that whatever valuation one comes<br/>up with, it will fail to reflect the actual values and value relations between benefits and costs. Both responses are<br/>argued to be problematic.}}, author = {{Herlitz, Anders}}, issn = {{1478-7547}}, language = {{eng}}, publisher = {{BioMed Central (BMC)}}, series = {{Cost Effectiveness and Resource Allocation}}, title = {{Effectiveness analysis and value incommensurability}}, url = {{http://dx.doi.org/10.1186/s12962-025-00624-w}}, doi = {{10.1186/s12962-025-00624-w}}, volume = {{25}}, year = {{2025}}, }